Flor Navarro

Flor Navarro

Auto-generated profile, based on publicly available information

Flor Navarro

Immunology and Immunotherapy Program, Center for Applied Medical Research, Cancer Center University of Navarra, Navarra Institute for Health Research, CIBERONC, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2015 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MTMatthew G. Thompson
Matthew G. Thompson
MLMichelle Larson
Michelle Larson
AVAmy Vidrine
Amy Vidrine
KBKelly Barrios
Kelly Barrios
FNFlor Navarro
Flor Navarro
SWStephanie K. Watkins
Stephanie K. Watkins
Tumor-associated myeloid cells, including dendritic cells (DCs) and macrophages, are immune suppressive. This study demonstrates a novel mechanism involving FOXO3 and NF-κB RelA that controls myeloid cell signaling and impacts their immune-suppressive nature. We find that FOXO3 binds NF-κB RelA in the cytosol, impacting both proteins by preventing FOXO3 degradation and preventing NF-κB RelA nuclear translocation. The location of protein–protein interaction was determined to be near the FOXO3 transactivation domain. In turn, NF-κB RelA activation was restored upon deletion of the same sequence in FOXO3 containing the DNA binding domain. We have identified for the first time, to our knowledge, a direct protein–protein interaction between FOXO3 and NF-κB RelA in tumor-associated DCs. These detailed biochemical interactions provide the foundation for future studies to use the FOXO3–NF-κB RelA interaction as a target to enhance tumor-associated DC function to support or enhance antitumor immunity.

31 October 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JKJared Klarquist
Jared Klarquist
KTKristen Tobin
Kristen Tobin
POPeyman Farhangi Oskuei
Peyman Farhangi Oskuei
SHSteven W. Henning
Steven W. Henning
MFManuel F. Fernandez
Manuel F. Fernandez
IPI. Caroline Le Poole
I. Caroline Le Poole
T regulatory cells (Treg) avert autoimmunity, but their increased levels in melanoma confer a poor prognosis. To explore the basis for Treg accumulation in melanoma, we evaluated chemokine expression in patients. A 5-fold increase was documented in the Treg chemoattractants CCL22 and CCL1 in melanoma-affected skin versus unaffected skin, as accompanied by infiltrating FoxP3+ T cells. In parallel, there was an approximately two-fold enhancement in expression of CCR4 in circulating Treg but not T effector cells. We hypothesized that redirecting Treg away from tumors might suppress autoimmune side effects caused by immune checkpoint therapeutics now used widely in the clinic. In assessing this hypothesis, we observed a marked increase in skin Treg in mice vaccinated with Ccl22, with repetitive vaccination sufficient to limit Treg accumulation and melanoma growth in the lungs of animals challenged by tumor cell injection, whether using a prevention or treatment protocol design. The observed change in Treg accumulation in this setting could not be explained by Treg conversion. Overall, our findings offered a preclinical proof of concept for the potential use of CCL22 delivered by local injection as a strategy to enhance the efficacious response to immune checkpoint therapy while suppressing its autoimmune side effects. Cancer Res; 76(21); 6230–40. ©2016 AACR.

1 May 2022 in OncoImmunology
Verified
Journal Article
Open access
FNFlor Navarro
Flor Navarro
NCNoelia Casares
Noelia Casares
CMCelia Martín-Otal
Celia Martín-Otal
ALAritz Lasarte-Cía
Aritz Lasarte-Cía
MGMarta Gorraiz
Marta Gorraiz
JLJuan José Lasarte
Juan José Lasarte
The high metabolic activity and insufficient perfusion of tumors leads to the acidification of the tumor microenvironment (TME) that may inhibit the antitumor T cell activity. We found that pharmacological inhibition of the acid loader chloride/bicarbonate anion exchanger 2 (Ae2), with 4,4’-diisothiocyanatostilbene-2,2’-disulfonicacid (DIDS) enhancedCD4+ andCD8+ T cell function upon TCR activation in vitro, especially under low pH conditions. In vivo, DIDS administration delayed B16OVA tumor growth in immunocompetent mice as monotherapy or when combined with adoptive T cell transfer of OVA-specificT cells. Notably, genetic Ae2 silencing in OVA-specificT cells improvedCD4+/CD8+ T cell function in vitro as well as their antitumor activity in vivo. Similarly, genetic modification of OVA-specificT cells to overexpress Hvcn1, a selectiveH+ outward current mediator that prevents cell acidification, significantly improved T cell function in vitro, even at low pH conditions. The adoptive transfer of OVA-specificT cells overexpressing Hvcn1 exerted a better antitumor activity in B16OVA tumor-bearingmice. Hvcn1 overexpression also improved the antitumor activity of CAR T cells specific for Glypican 3 (GPC3) in mice bearing PM299L-GPC3tumors. Our results suggest that preventing intracellular acidification by regulating the expression of acidifier ion channels such as Ae2 or alkalinizer channels like Hvcn1 in tumor-specificlymphocytes enhances their antitumor response by making them more resistant to the acidic TME. Graphical abstract

11 December 2025 in Blood
Verified
Journal Article
Open access
FNFlor Navarro
Flor Navarro
TLTeresa Lozano
Teresa Lozano
AFAndrea Fuentes-García
Andrea Fuentes-García
ISInés Sánchez-Moreno
Inés Sánchez-Moreno
MLMarta Larrayoz
Marta Larrayoz
JLJuan José Lasarte
Juan José Lasarte
Glutamine dependence of cancer cells reduces local glutamine availability, which hinders antitumor T-cell functionality and facilitates immune evasion. We thus speculated that glutamine deprivation might be limiting efficacy of chimeric antigen receptor (CAR) T-cell therapies in patients with cancer. We have seen that antigen-specific T cells are unable to proliferate or produce interferon gamma (IFN-γ) in response to antigen stimulation when glutamine concentration is limited. Using multiple myeloma (MM) as a glutamine-dependent disease model, we found that murine CAR T cells selectively targeting B-cell maturation antigen (Bcma) in MM cells were sensitive to glutamine deprivation. However, CAR T cells engineered to increase glutamine uptake by expression of the glutamine transporter Asct2 exhibited enhanced proliferation and responsiveness to antigen stimulation, increased production of IFN-γ, and heightened cytotoxic activity, even under conditions of low glutamine concentration. Mechanistically, Asct2 overexpression reprogrammed the metabolic fitness of CAR T cells by upregulating the mechanistic target of rapamycin complex 1 gene signature, modifying the solute carrier transporter repertoire, and improving both basal oxygen consumption rate and glycolytic function, thereby enhancing CAR T-cell persistence in vivo. Accordingly, expression of Asct2 increased the efficacy of Bcma-CAR T cells in syngeneic and genetically engineered mouse models of MM, which prolonged mouse survival. In patients, higher-level expression of ASCT2 by MM cells predicted poor outcome to combined immunotherapy and BCMA-CAR T-cell therapy. Our results indicate that reprogramming glutamine metabolism may enhance antitumor CAR T-cell functionality in MM. This approach may also be effective for other cancers that depend on glutamine as a key energy source and metabolic hallmark.

22 February 2017 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MTMatthew G. Thompson
Matthew G. Thompson
DPDaniel S. Peiffer
Daniel S. Peiffer
MLMichelle Larson
Michelle Larson
FNFlor Navarro
Flor Navarro
SWStephanie K. Watkins
Stephanie K. Watkins

27 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ALAritz Lasarte-Cia
Aritz Lasarte-Cia
TLTeresa Lozano
Teresa Lozano
DCDavid Cano
David Cano
CMCelia Martín-Otal
Celia Martín-Otal
FNFlor Navarro
Flor Navarro
JLJuan José Lasarte
Juan José Lasarte
Background/Aim. Irreversible electroporation (IRE) showed promising results for small‐size tumors and very early cancers. However, further development is needed to evolve this procedure into a more efficient ablation technique for long‐term control of tumor growth. In this work, we show that it is possible to increase the antitumor efficiency of IRE by simmultaneously injecting c‐di‐GMP, a STING agonist, intratumorally. Materials and Methods. Intratumoral administration of c‐di‐GMP simultaneously to IRE was evaluated in murine models of melanona (B16.OVA) and hepatocellular carcinoma (PM299L). Results. The combined therapy increased the number of tumor‐infiltrating IFN‐γ/TNF‐α‐producing CD4 and CD8 T cells and delayed tumor growth, as compared to the effect observed in groups treated with c‐di‐GMP or IRE alone. Conclusion. These results can lead to the development of a new therapeutic strategy for the treatment of cancer patients refractory to other therapies.